Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Complete Title: A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145/LN-145-S1) in Patients with Solid Tumors
Trial Phase: II
Investigator: Sylvia Lee
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with pembrolizumab or TIL LN-145/LN-145-S1 as a single therapy.
Keywords:
- Lung Carcinoma, Non-Small-Cell (NSCLC)
- Neoplasms, Squamous Cell
- Neoplasm Metastasis
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
Pediatric
II
Sylvia Lee
RG1003670
NCT03645928
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145/LN-145-S1) in Patients with Solid Tumors
Lung Carcinoma, Non-Small-Cell (NSCLC)
Neoplasms, Squamous Cell
Neoplasm Metastasis